Avience Biomedicals IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2024 | 2025 | Jan 2026 |
|---|---|---|---|
| Revenue | 24.37 | 45.97 | 41.94 |
| Expense | 21.43 | 36.17 | 34.06 |
| Profit (PAT) | 2.14 | 7.23 | 5.74 |
| Total Assets | 34.65 | 56.52 | 66.07 |
Promoters: Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 40,31,256 | 87.89% |
| Promoter Holding Post Issue | 54,85,056 | 64.59% |
Strengths & Risks
- Heavily oversubscribed — 385.4x overall (so far).
- Strong institutional (QIB) demand — 196.8x.
- Revenue grew 89% in the latest reported year.
- Solid profit margin — 15.7%.
- Strong return on equity — 50%.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products. Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
| Purpose | Amount (Cr) |
|---|---|
| Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 15.96 |
| Funding the working capital requirements of the Company | 8.25 |
| General Corporate Purpose | - |
Resources & Documents
Avience Biomedicals Ltd., C-11, Block-C, Community Centre,, Janakpuri A-3,, Delhi, New Delhi, 110058
Avience Biomedicals has set a price band of Rs 196–Rs 208 per share for an issue size of Rs 30 crore. The stock listed with a 90.00% gain versus its issue price on June 25, 2026.
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD).
The issue is promoted by Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary with Fintellectual Corporate Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 2… (Rs 16 crore) and Funding the working capital requirements of the Company (Rs 8 crore).
Grey market is quoting a premium of +Rs 107 (+51.4% over issue price), up Rs 44 from the previous session. Final subscription data records overall subscription at 385.40x, retail at 401.36x, QIB at 196.77x, NII at 597.63x.
On fundamentals, the company is posting revenue growth of 88.6%, a profit margin of 15.7%, return on equity of 49.9% in its most recent reported period.
Our data-driven engine currently flags this issue as a Strong Subscribe — the data suggests strong listing-day potential backed by healthy fundamentals. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Avience Biomedicals IPO GMP — What It Means
The latest grey market premium for Avience Biomedicals IPO is ₹107 (+51.4%). GMP is an unofficial, dealer-quoted figure that hints at expected listing-day demand — it is not a guaranteed listing price. For Avience Biomedicals it should be read alongside the subscription numbers and the company's fundamentals, since grey-market premiums can swing sharply during the bidding window.
See the full Avience Biomedicals GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!